Name: UROGEN PHARMA LTD (URGN) Stock
Brand: UROGEN PHARMA LTD
Rating: 7 (3 reviews)

URGN Latest News, Press Relases and Analysis

All

Press Releases

10 days ago - By: Chartmill

UROGEN PHARMA LTD (NASDAQ:URGN) Reports Q3 2025 Earnings: Revenue Misses, Loss Per Share Beats

10 days ago - By: The Motley Fool

UroGen (URGN) Q3 2025 Earnings Call Transcript

10 days ago - By: UroGen Pharma Ltd.

UroGen Reports Third Quarter 2025 Financial Results as ZUSDURI™ Launch Gains Momentum

10 days ago - By: UroGen Pharma Ltd.

UroGen Reports Third Quarter 2025 Financial Results as ZUSDURI™ Launch Gains Momentum

10 days ago - By: UroGen Pharma Ltd.

UroGen Reports 77.8% Three-Month Complete Response Rate from Phase 3 UTOPIA Trial of UGN-103 and Receives FDA Agreement on NDA Submission Strategy in Recurrent LG-IR-NMIBC Based on UTOPIA Trial

10 days ago - By: UroGen Pharma Ltd.

UroGen Reports 77.8% Three-Month Complete Response Rate from Phase 3 UTOPIA Trial of UGN-103 and Receives FDA Agreement on NDA Submission Strategy in Recurrent LG-IR-NMIBC Based on UTOPIA Trial

10 days ago - By: Benzinga - Mentions: STVN PODD AMRK SOLV ...

Earnings Scheduled For November 6, 2025

12 days ago - By: UroGen Pharma Ltd.

UroGen Pharma to Present at Guggenheim Securities Healthcare Innovation Conference

12 days ago - By: UroGen Pharma Ltd.

UroGen Pharma to Present at Guggenheim Securities Healthcare Innovation Conference

17 days ago - By: Zacks Investment Research - Mentions: FENC

Adherex Technologies Inc. (FENC) May Report Negative Earnings: Know the Trend Ahead of Q3 Release

17 days ago - By: UroGen Pharma Ltd.

UroGen Pharma to Report Third Quarter 2025 Financial Results on Thursday, November 6th, 2025

17 days ago - By: UroGen Pharma Ltd.

UroGen Pharma to Report Third Quarter 2025 Financial Results on Thursday, November 6th, 2025

18 days ago - By: Zacks Investment Research - Mentions: CRSP

Urogen Pharma (URGN) Expected to Beat Earnings Estimates: Should You Buy?

20 days ago - By: UroGen Pharma Ltd.

Centers for Medicare and Medicaid Services Assigns Permanent J Code for ZUSDURI™ Effective January 1, 2026

2 months ago - By: UroGen Pharma Ltd.

ZUSDURI™ Clinical Review Published in Reviews in Urology™ Highlights Durable Efficacy and Manageable Safety Profile in Recurrent Low-Grade, Intermediate-Risk Non–Muscle Invasive Bladder Cancer

2 months ago - By: UroGen Pharma Ltd.

ZUSDURI™ Clinical Review Published in Reviews in Urology™ Highlights Durable Efficacy and Manageable Safety Profile in Recurrent Low-Grade, Intermediate-Risk Non–Muscle Invasive Bladder Cancer

2 months ago - By: UroGen Pharma Ltd.

UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

2 months ago - By: UroGen Pharma Ltd.

UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

3 months ago - By: UroGen Pharma Ltd.

UroGen Pharma to Present at Upcoming Investor Conferences

3 months ago - By: UroGen Pharma Ltd.

UroGen Pharma to Present at Upcoming Investor Conferences

3 months ago - By: The Motley Fool

UroGen (URGN) Q2 Revenue Rises 11%

3 months ago - By: Zacks Investment Research - Mentions: TCRX

Urogen Pharma (URGN) Reports Q2 Loss, Lags Revenue Estimates

3 months ago - By: UroGen Pharma Ltd.

UroGen Pharma Expands Commercial Portfolio with Launch of ZUSDURI™ and Reports Second Quarter 2025 Financial Results

3 months ago - By: UroGen Pharma Ltd.

UroGen Pharma Expands Commercial Portfolio with Launch of ZUSDURI™ and Reports Second Quarter 2025 Financial Results

3 months ago - By: Benzinga - Mentions: GSAT PGY ADV REAL ...